top of page
Wegovy (Semaglutide)
Wegovy (semaglutide) is an injectable medication that is used with a reduced-calorie diet and increased exercise to help manage chronic weight in adults who are: Obese (body mass index = 30 kg/m2) OR, Overweight (body mass index = 27 kg/m2) with at least one weight-related condition (e.g., high blood pressure, diabetes, high cholesterol) Wegovy is classified as aglucagon-like peptide-1(GLP-1) receptor agonist. Fact Table Formula C187H291N45O59 License EU EMA, US FDA Bioavailability 89% Legal status Rx-Only Chemical Name Semaglutide Elimination half-life 7 days Dosage (Strength) 0.5mg pen of 0.5mg/0.5ml, 0.25mg pens of 0.25mg/0.5ml,  1mg pens of 1mg/0.5ml, 1.7mg pens of 1.7mg/0.75ml, 2.4mg pens of 2.4mg/0.75ml Pregnancy Not Recommended Brands Wegovy Protein binding More than 99% PubChem CID 56843331 MedlinePlus a618008 ChEBI 167574 ATC code A10BJ06 DrugBank DB13928 KEGG D10025 Routes of administration Subcutaneous

Wegovy (Semaglutide)

  • Wegovy is available in a pre-filled pen that delivers a single-dose of either 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg. Wegovy should be injected subcutaneously into the abdomen, thigh, or upper arm one time a week, on the same day each week. Wegovy may be administered with or without food. If you have any questions about using Wegovy, ask your doctor or pharmacist. The typical starting dose is 0.25 mg one time a week for 4 weeks. Your doctor may increase your dose every 4 weeks until you reach 2.4 mg once weekly. The maintenance dose is 2.4 mg one time a week. If you have type 2diabetes, be sure to check your blood sugar before starting and during treatment with Wegovy.
bottom of page